Clinical Trials Logo

Leishmaniasis, Visceral clinical trials

View clinical trials related to Leishmaniasis, Visceral.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03013673 Terminated - Clinical trials for Leishmaniasis, Visceral

Predicting Visceral Leishmaniasis in HIV Infected Patients

PreLeisH
Start date: October 11, 2017
Phase:
Study type: Observational

In this cohort study, the investigators will study the asymptomatic period preceding the onset of active Visceral Leishmaniasis (VL) in HIV-infected individuals from VL endemic regions in Ethiopia as an avenue to develop an evidence-based screen and treat strategy to prevent progression to active VL.

NCT ID: NCT02839603 Terminated - Clinical trials for Visceral Leishmaniasis

Asymptomatic Leishmania Infection in HIV Patients

Start date: September 2015
Phase:
Study type: Observational

To collect pilot data on the prevalence and incidence of asymptomatic Leishmania donovani infection in HIV infected individuals in a visceral leishmaniasis (VL)-HIV endemic region to inform the feasibility of a larger study exploring a screen and treat strategy for VL in HIV co-infected individuals in East-Africa (Ethiopia).

NCT ID: NCT01980199 Terminated - Clinical trials for Visceral Leishmaniasis

Trial to Determine Efficacy of Fexinidazole in Visceral Leihmaniasis Patients in Sudan

Start date: November 2013
Phase: Phase 2
Study type: Interventional

This study is designed to determine the efficacy of Fexinidazole as an oral treatment in Visceral Leishmanisasis sudanese adults patients. The results of this proof of concept study will allow to make a decision on whether to proceed with clinical development of Fexinidazole for visceral leishmaniasis.

NCT ID: NCT01310738 Terminated - Clinical trials for Visceral Leishmaniasis

Efficacy and Safety Study of Drugs for Treatment of Visceral Leishmaniasis in Brazil

LVBrasil
Start date: February 2011
Phase: Phase 4
Study type: Interventional

This study is aimed to compare the efficacy and safety of medications currently used in Brazil for treatment of visceral leishmaniasis. The investigators will compare the effects of meglumine antimoniate, two formulations of amphotericin B: deoxycholate and liposomal, and a combination of meglumine plus the liposomal amphotericin B formulation. The study is designed to demonstrate the difference in efficacy measured as cure rate at six months after treatment and the safety profile based on the adverse event rate observed with each intervention.

NCT ID: NCT00832208 Terminated - Clinical trials for Visceral Leishmaniasis

Open-Label, Sequential Step, Safety and Efficacy Study to Determine the Optimal Single Dose of Ambisome for Patients With VL

Start date: April 2009
Phase: Phase 2
Study type: Interventional

This is a phase II/III open, comparative dose trial to find the lowest single dose of AmBisome for the treatment of primary, symptomatic visceral leishmaniasis(VL), in HIV negative patients. In this trial, the minimum effective dose will be determined in a sequential step, dose escalation design, which minimises the number of patients exposed to low, potentially inadequate doses and provides contemporaneous comparative data against the manufacturer's recommended dose schedule in this indication.

NCT ID: NCT00378495 Terminated - Kala Azar Clinical Trials

Miltefosine for Brazilian Visceral Leishmaniasis

Start date: April 2005
Phase: Phase 1/Phase 2
Study type: Interventional

Miltefosine will be administered to Brazilian patients with kala azar